| FENNEC PHARMACEUTICALS |
| Kanada |
| Gesundheit |
| CA31447P1009 / A12A5F |
| RV41 (Frankfurt) / FENC (NASDAQ) |
| FRA:RV41, ETR:RV41, RV41:GR, NASDAQ:FENC |
| - |
| https://fennecpharma.com/ |
|
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed..
>Volltext.. |
| 342.4 Mio. EUR |
| 306.32 Mio. EUR |
| 50.72 Mio. EUR |
| -1.32 Mio. EUR |
| -3.09 Mio. EUR |
| -0.11 EUR |
| - |
| 35.33 Mio. EUR |
| -3.33 Mio. EUR |
| 3.33 |
| 83.42% |
| 68.11% |
| - |
| - |
| - |
| FENNEC |
| 28.08.26 |
|
||||
|